Press release
Hypoparathyroidism Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX
"Hypoparathyroidism Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoparathyroidism Market.
The Hypoparathyroidism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypoparathyroidism Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Hypoparathyroidism treatment therapies with a considerable amount of success over the years.
*
Hypoparathyroidism companies working in the treatment market are Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX Bioscience, Amorphical Ltd., Entera Bio Ltd., Visen Pharmaceuticals, and others, are developing therapies for the Hypoparathyroidism treatment
*
Emerging Hypoparathyroidism therapies in the different phases of clinical trials are- TRANSCON PTH (palopegteriparatide), Encaleret (BBP-305/CLTX-305), AZP-3601 (eneboparatide), MBX 2109, AMOR-1, EBP05, TransCon PTH, and others are expected to have a significant impact on the Hypoparathyroidism market in the coming years.
*
In August 2024, US biotechnology firm MBX Biosciences has administered the first dose to a participant in a Phase II trial for MBX 2109, a potential therapy for chronic hypoparathyroidism (HP). The Avail trial is designed as a randomized, double-blind, placebo-controlled study, enrolling 48 adult patients with Hypoparathyroidism.
*
In August 2024, Ascendis Pharma has received approval from the US Food and Drug Administration (FDA) for its drug YORVIPATH (palopegteriparatide) to treat hypoparathyroidism in adults. Hypoparathyroidism is a rare endocrine disorder marked by inadequate levels of parathyroid hormone, which impacts various organs. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is given once daily.
Hypoparathyroidism Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH) from the parathyroid glands. PTH is crucial for regulating calcium and phosphorus levels in the body. The deficiency of PTH leads to low calcium levels (hypocalcemia) and high phosphorus levels (hyperphosphatemia), resulting in symptoms such as muscle cramps, tingling in the extremities, fatigue, and in severe cases, seizures or cardiac issues. The condition can be caused by surgical removal of the parathyroid glands, autoimmune disorders, genetic factors, or idiopathic reasons. Treatment typically involves calcium and vitamin D supplementation to manage symptoms and maintain normal calcium levels.
Get a Free Sample PDF Report to know more about Hypoparathyroidism Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypoparathyroidism-pipeline-insight [https://www.delveinsight.com/report-store/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Hypoparathyroidism Drugs Under Different Phases of Clinical Development Include:
*
TRANSCON PTH (palopegteriparatide): Ascendis Pharma
*
Encaleret (BBP-305/CLTX-305): Bridgebio/Calcilytix Therapeutics
*
AZP-3601 (eneboparatide): Amolyt Pharma
*
MBX 2109: MBX Bioscience
*
AMOR-1: Amorphical Ltd.
*
EBP05: Entera Bio Ltd.
*
TransCon PTH: Visen Pharmaceuticals
Hypoparathyroidism Route of Administration
Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Hypoparathyroidism Molecule Type
Hypoparathyroidism Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Hypoparathyroidism Pipeline Therapeutics Assessment
*
Hypoparathyroidism Assessment by Product Type
*
Hypoparathyroidism By Stage and Product Type
*
Hypoparathyroidism Assessment by Route of Administration
*
Hypoparathyroidism By Stage and Route of Administration
*
Hypoparathyroidism Assessment by Molecule Type
*
Hypoparathyroidism by Stage and Molecule Type
DelveInsight's Hypoparathyroidism Report covers around 10+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Hypoparathyroidism product details are provided in the report. Download the Hypoparathyroidism pipeline report to learn more about the emerging Hypoparathyroidism therapies [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Hypoparathyroidism Therapeutics Market include:
Key companies developing therapies for Hypoparathyroidism are - Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche Ltd, ProLynx, Inc., Extend Biosciences, Inc., Takeda Pharmaceutical Company Limited., Entera Bio Ltd., BionPharma Inc., Teva Pharmaceuticals Ltd., and others.
Hypoparathyroidism Pipeline Analysis:
The Hypoparathyroidism pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Hypoparathyroidism with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoparathyroidism Treatment.
*
Hypoparathyroidism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Hypoparathyroidism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoparathyroidism market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypoparathyroidism drugs and therapies [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypoparathyroidism Pipeline Market Drivers
*
Rising Incidence, Advancements in Research, Increased Awareness, Regulatory Support, Improved Diagnostic Techniques, are some of the important factors that are fueling the Hypoparathyroidism Market.
Hypoparathyroidism Pipeline Market Barriers
*
However, High Treatment Costs, Limited Market Size, Complexity of Treatment, Complexity of Treatment, Limited Clinical Data, and other factors are creating obstacles in the Hypoparathyroidism Market growth.
Scope of Hypoparathyroidism Pipeline Drug Insight
*
Coverage: Global
*
Key Hypoparathyroidism Companies: Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX Bioscience, Amorphical Ltd., Entera Bio Ltd., Visen Pharmaceuticals, and others
*
Key Hypoparathyroidism Therapies: TRANSCON PTH (palopegteriparatide), Encaleret (BBP-305/CLTX-305), AZP-3601 (eneboparatide), MBX 2109, AMOR-1, EBP05, TransCon PTH, and others
*
Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies
*
Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers
Request for Sample PDF Report for Hypoparathyroidism Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hypoparathyroidism-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hypoparathyroidism Report Introduction
2. Hypoparathyroidism Executive Summary
3. Hypoparathyroidism Overview
4. Hypoparathyroidism- Analytical Perspective In-depth Commercial Assessment
5. Hypoparathyroidism Pipeline Therapeutics
6. Hypoparathyroidism Late Stage Products (Phase II/III)
7. Hypoparathyroidism Mid Stage Products (Phase II)
8. Hypoparathyroidism Early Stage Products (Phase I)
9. Hypoparathyroidism Preclinical Stage Products
10. Hypoparathyroidism Therapeutics Assessment
11. Hypoparathyroidism Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypoparathyroidism Key Companies
14. Hypoparathyroidism Key Products
15. Hypoparathyroidism Unmet Needs
16 . Hypoparathyroidism Market Drivers and Barriers
17. Hypoparathyroidism Future Perspectives and Conclusion
18. Hypoparathyroidism Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoparathyroidism-pipeline-drugs-analysis-report-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-ascendis-pharma-bridgebiocalcilytix-therapeutics-amolyt-pharma-mbx]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypoparathyroidism Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Ascendis Pharma, Bridgebio/Calcilytix Therapeutics, Amolyt Pharma, MBX here
News-ID: 3669356 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Hypoparathyroidism
Hypoparathyroidism Market Size, Development, Key Opportunity, Application & Fore …
The global hypoparathyroidism market was valued at approximately $1.3 billion in 2023 and is projected to reach around $2.5 billion by 2031. This represents a compound annual growth rate (CAGR) of about 8.8%.
Request a Free Sample Copy@ https://www.datalibraryresearch.com/sample-request/hypoparathyroidism-market-5438
With market research reports garnering immense significance in the speedily transforming market place, the team at Data Library Research endows with Hypoparathyroidism Market report in a way which is predicted. It comprehensively…
Hypoparathyroidism Drug Market: An Overview
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to low calcium levels in the blood. This deficiency causes various complications, including muscle cramps, fatigue, and neurological issues. Managing hypoparathyroidism primarily involves calcium and vitamin D supplements, but newer treatments targeting PTH replacement therapy have emerged, providing more effective and sustainable solutions.
The development of hypoparathyroidism drugs represents a promising area of growth in the…
Hypoparathyroidism Drug Market Size, Share, Trends, Demand, Growth and Competiti …
"Hypoparathyroidism Drug Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Hypoparathyroidism Drug Market report includes basic, secondary and advanced information related to the global…
Hypoparathyroidism Drug Market Size, Share, Trends, Growth and Competitive Analy …
Hypoparathyroidism Drug Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Hypoparathyroidism Drug Market report includes basic, secondary and advanced information related to the global…
Hypoparathyroidism Treatment Market Size 2024 to 2031.
Market Overview and Report Coverage
Hypoparathyroidism is a rare condition where the parathyroid glands in the neck produce too little parathyroid hormone, resulting in low calcium levels in the blood. The primary treatment for hypoparathyroidism involves calcium and vitamin D supplementation, as well as hormonal therapy.
The future outlook for the Hypoparathyroidism Treatment Market is promising, with a projected growth rate of 20.00% during the forecasted period. This growth can…
Hypoparathyroidism Treatment Market Size, Share, Trends, Analysis and Forecast 2 …
The Global Hypoparathyroidism Treatment Market is poised to register a CAGR of over 8% during the forecast period 2020 to 2027.
Hypoparathyroidism occurs when the parathyroid glands does not produce enough hormone. Hyperparathyroidism can be caused by a number of factors, including injury or removal of the parathyroid glands, DiGeorge syndrome, an autoimmune disease, cancer radiation treatment, and low magnesium levels. The main function of parathyroid hormone is to regulate blood…
